For the purpose of this chapter, the following definitions shall apply unless the context clearly indicates or requires a different meaning.
CANNABIMIMETIC AGENTS.
(1) Any substance that is a cannabinoid receptortypel (CBl receptor) agonist as demonstrated by binding studies and functional assays within the following structural classes:
(a) 2-(3-hydroxycyclohexyl) phenol with substitution at the S-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent;
(b) 3-(1-naphthoyl) indole or 3-(1-naphthyl) indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent;
(c) 3-(1-naphthoyl) pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the naphthoyl ring to any extent;
(d) 1-(1-naphthylmethyl) indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent; and
(e) 3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent; including, but not limited to, 5-(1,1-dimethylheptyl)- 2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497); 5-(1,1-dimethyloctyl)- 2-[(1R,3S)- 3-hydroxycyclohexyl]-phenol [cannabicyclohexanol or CP-47,497 CS-homolog); 1-pentyl-3- (1-naphthoyl) indole (JWH-018 and AM678); 1-butyl-3-(1-naphthoyl) indole (JWH-073); l-hexyl-3- (1-naphthoyl) indole (JWH-019); 1-[2-(4-morpholinyl) ethyil-3-(1-naphthoyl) indole (JWH-200); 1-pentyl-3- (2-methoxyphenylacetyl) indole (JWH-250); 1-pentyl-3-[1- (4-methoxynaphthoyl)3 indole (JWH-081); 1-pentyl- 3-(4-methyl-1-naphthoyl) indole (JWH-122); 1-pentyl-3- (4-chloro-1-naphthoyl) indole (JWH-398); 1-(5-fluoropentyl)-3-(1-naphthoyl) indole (AM-2201); 1- (5-fluoropentyl)- 3-(2-iodobenzoyl) indole (AM-694); 1-pentyl-3- [(4-methoxy)-benzoyl) indole (SR-19 and RCS-4); 1-cyclohexylethyl-3-(2-methoxyphenylacetyl) indole (SR-18 and RCS-8); 1-pentyl-3- (2-chlorophenylacetyl) indole (JWH-203).
(2) The term shall not include cannabimimetic agents that require a prescription, are approved by the United States Food and Drug Administration, and are dispensed in accordance with state and federal law.
PERSON. Individual, corporation, government or governmental subdivision or agency, business trust, estate, trust, partnership or association, or any other legal entity.
POSSESSION. To have actual physical possession or otherwise to exercise actual dominion or control over a tangible object.
SYNTHETIC CANNABINOIDS. Any substance that contains 1-pentyl-3-(1-naphthoyl) indole (JWH-018); 1-pentyl-3- (4-methyl-1-naphthoyl) indole (JWH-122); 1-pentyl-3-(4-methoxyphenylacetyl) indole (JWH-201); 1-pentyl-3- (2-chlorophenylacetyl) indole (JWH-203); 1-pentyl-3- (4-methoxy-1-naphthoyl) indole (JWH-081); 1-pentyl-3-(4-ethyl-1-naphthoyl) indole (JWH-210); 1-pentyl-3-(2-methoxyphenylacetyl) indole (JWH-250); 1-pentyl-3- (3-methoxyphenylacetyl) indole (JWH-302); 1-(5-fluoropentyl)-3- (1-naphthoyl) indole (AM-2201); 1-pentyl-3-(4-methoxybenzoly) indole (RCS-4); pravadoline (WIN 48,098); desoxypipradrol; 4-methyl-N-ethylcathinone (4-MEC); 9-nor-9B-Hydroxyhexahydrocannabinol (HHC); any synthetic cannabinoids outlawed by state and federal laws, including, but not limited to, KRS 218A.010(51). The term shall not include synthetic cannabinoids that require a prescription, are approved by the United States Food and Drug Administration, and are dispensed in accordance with state and federal law.
TRAFFIC. To manufacture, distribute, dispense, sell, transfer or possess with intent to manufacture, distribute, dispense or sell a controlled substance.
TRANSFER. To dispose of a controlled substance to another person without consideration and not in furtherance of commercial distribution.
(Ord. 2011-15, passed 11-28-2011)